Background CD44 has been linked to favorable prognosis in neuroblastoma and in the present study we investigate if it can be used to prospectively isolate neuroblastomainitiating cells. Methods To define the cancer-initiating properties of CD44 positive and negative cells, we FACS-sorted the SK-N-SH neuroblastoma cell line on the basis of CD44 expression and proceeded to phenotypically and molecularly characterize the two cell subpopulations. Results We found that CD44 defines two morphologically distinctive cell populations with different adhesion molecule profiles, and that CD44 negative cells expressed higher levels of the neuroblastoma-initiating cell marker CD24. When inoculated subcutaneously into NOD/SCID animals, the CD44 negative cells were capable of tumor formation and organ infiltration, clearly demonstrating an inverse correlation of CD44 expression and neuroblastoma metastases formation. Gene expression analysis revealed that CD44 defines molecularly discrete cell types with the CD44 negative cells expressing proteins associated with uncontrolled cell cycle progression, immune evasion and a reduced capacity to undergo apoptosis. Conclusion Collectively, our findings show that CD44 negative neuroblastoma cells possess all the phenotypic and molecular features required for a cancer-initiating cell.
Introduction
The cancer stem cell concept was originally proven in myeloid leukemia [1] but accumulating evidence suggests that solid tumors as well contain a small fraction of cells capable of self-renewal and cancer propagation. The discovery of cancer stem cells is of prime clinical importance as it emphasizes their potential role in tumor maintenance, minimal residual disease and metastasis. As a result, identifying their precise phenotype and molecular identity will aid the therapeutic targeting of many malignancies [2] .
The phenotype of cancer stem cells is under extensive investigation and in many cases it seems to resemble that of normal stem cells. For example, medulloblastoma and glioblastoma-initiating cells express CD133, a marker also associated with normal hematopoietic progenitor cells [3, 4] . In addition, many tumors contain a Hoechst dye efflux sidepopulation (SP) of cells, denoting the presence of drugresistance pumps that possibly bestows these cells with an inherent chemotherapy resistance attribute similar to normal tissue stem cells [5] . Neuroblastoma is a tumor of the sympathetic nervous system and comprises the most common extracranial solid tumor in children. Its clinical presentation is characterized by heterogeneity, ranging from spontaneous regression to aggressive and metastatic behavior in advanced stages. It is postulated that the observed clinical outcomes may arise from variability in the cancer stem cell content and additional genetic changes of the involved neuroblasts [6, 7] . CD44 is a transmembrane glycoprotein which mediates cell to cell interactions and attachment to extracel-lular matrix mainly through hyaluronic acid. It has many isoforms resulting from alternative splicing or post-transcriptional glycosylation [8] , and their expression can be modulated by differentiation or mitogenic factors [9] . The prognostic significance of CD44 expression varies considerably depending on the isoform and the malignancy in question. In general terms, certain CD44 variant expression or loss of the standard isoform (CD44s) are unfavourable prognostic factors. In malignancies of the hematopoietic system, including myeloid leukemias, B-CLL, lymphomas and thymomas, CD44 variant expression is associated with poor prognosis [10] . Similar observations are made for breast and colon carcinomas [11, 12] . In ovarian carcinoma and neuroblastoma, however, CD44 expression is linked with better prognosis [13] . CD44 expression in neuroblastoma comprises a strong prognostic marker alongside tumor stage [14, 15] and is reversely correlated with N-myc amplification [16] .
In this study, we have investigated whether CD44 can be used as a marker to prospectively isolate tumor-initiating neuroblastoma cells. We observed that CD44 not only defines morphological differences between the positive and negative cell fractions of the SK-N-SH cell line, but these two populations behaved differently in vivo. Cells lacking CD44 expression formed subcutaneous tumors in NOD/ SCID animals and were also capable of bone marrow and spleen infiltration, strongly supporting their metastatic potential. Gene expression analysis revealed a reduced ability to undergo apoptosis, enhanced immune evasion and uncontrolled cell cycle progression in the CD44 negative cell subpopulation, further supporting their cancer-initiating identity.
Materials and methods

Cell lines and animals
The neuroblastoma cell line SK-N-SH was a kind gift from Dr Bonnet (Cancer Research UK, London) and was cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin (all from Invitrogen, UK). NOD/ SCID animals were bred in house and maintained in microisolators under sterile conditions. Animals aged 8-12 weeks were conditioned with two intraperitoneal injections of 20 mg/kg Busilvex 48 h and 24 h prior to transplantation [17] . The indicated number of sorted SK-N-SH cells was mixed with Matrigel (BD Biosciences, Greece) at 1:1 ratio and injected subcutaneously on the right flank of each animal. Tumor growth was monitored over time and animals were sacrificed when tumor diameter reached 1.3 cm.
Flow cytometry
Neuroblastoma cells were stained with anti-human CD44-PE (clone 515) or -APC (clone G44-26) (both from BD Biosciences) that recognize the standard isoform of CD44. In addition, antibodies for CXCR4, CD24, CD29 (β1 integrin), CD49d (α4 integrin), CD49e (α5 integrin), CD106, CD54, CD58, GD2 (all from BD Biosciences) or N-cadherin (Sigma Aldrich, Greece) were used to stain the neuroblastoma cells. Secondary rat anti-mouse IgG2a FITC or IgG1 FITC antibodies were used for detection. Propidium iodide or 7-AAD (Sigma Aldrich) was used to determine cell viability. Samples were run on a Beckman Coulter FC500 flow cytometer and analysis was performed using CXP Analysis software (Beckman Coulter, USA).
Isolation of CD44 positive and negative SK-N-SH populations was performed by FACS sorting on a BD AriaI ™ (BD Biosciences) following staining with PEconjugated anti-human CD44 antibody (BD Biosciences). 7-AAD was used to exclude dead cells. Sorted populations were collected at >97% purity and were either injected the same day or cultured in vitro for further observation.
Cell proliferation
The two CD44 subpopulations were seeded in 6-well plates at 2×10 5 cells/well and 4-5 days later, the cells were detached using trypsin (Gibco) and counted on a hemocytometer using trypan blue exclusion. Half of the medium was replenished every 2 days. The cell doubling time between two time points was calculated using the equation:
where N and N 0 are the cell numbers at t and t 0 , respectively. At least 6 time points were calculated for each sorted CD44 cell population. We also measured the cell proliferation at various time points during in vitro culture cells by the CellTiter 96® Aqueous One Solution (Promega, UK) according to the manufacturer's recommendations. Cells were plated at 10 4 per well in a 96-well plate, the solution added after 48-72 h and the OD490nm was read 2-4 h later.
Neuroblastoma organ infiltration analysis
On the day of sacrifice, single cell suspensions were obtained from the subcutaneous tumor, spleen and liver of the animals by passing minced tissue through a 100 μm cell strainer. Bone marrow cells were obtained by flushing the tibiae and femurs. Red blood cell lysis was performed in 0.7% NH 4 Cl and for the detection of neuroblastoma micrometastases, we performed PCR on phenol-chloroform-extracted DNA from the aforementioned tissues using human-specific primers for CART-1 (F: 5'-AAGGATACCACAATAAGCTGC-3'; R: 5'-GGTTTGTGGAGACTGGCAC-3'). Primers for mouse TNF-alpha (F: 5'-GGCTTTCCGAATTCACTGGAG -3'; R: 5'-CCCCGGCCTTCCAAATAAA -3') were used as a control. PCR conditions were 95°C for 5 min followed by 34 cycles of 95°C for 1 min, 60°C for 1 min, 72°C for 1 min. Analysis of PCR products was performed by agarose gel electrophoresis.
RT-PCR for CD44 isoform expression
RNA from freshly sorted SK-N-SH cells was extracted using TRI Reagent (MRC, USA) and reverse transcription was performed using MMLV-RT (Promega) according to the manufacturer's recommendations. Primer sequences for CD44 standard and variant isoforms and PCR conditions were as previously described [9] .
Quantitative Taqman PCR
Real-time PCR was performed using 2xSYBR Green PCR Master Mix (Fermentas or Stratagene, UK). All samples were analyzed in duplicate 25μl reactions on an ABI Prism R 7000 Sequence Detector (Applied Biosystems, USA). Primers were as follows:
Gene expression analysis
Total RNA was obtained from sorted CD44 positive or negative cells after in vitro culture, using TRI Reagent (MRC, USA). Further RNA purification and reverse transcription were performed according to SABiosciences' recommendations using the RT 2 qPCR-Grade RNA Isolation kit and RT 2 First Strand kit, respectively. Gene expression analysis in CD44 negative cells compared to the CD44 positive cell population was done using the Signal Transduction Pathway Finder Super Arrays (SA Biosciences, USA). Two biological replicates were tested for each CD44 cell population.
Cell cycle
CD44 positive or negative SK-N-SH cells were fixed in 4% paraformaldehyde for 30 min at RT, followed by permeabilization with 0.2% Triton X100 for 30 min at RT. DNA staining was performed with propidium iodide (1.6 mg/ml) in the presence of 2.5 mg/ml RNase (Sigma) for 30 min at 37°C and analysis was performed on FC500 (Beckman Coulter). Similar protocol for cell cycle analysis was performed for cells treated with 3 nmol 5FU for 48 h. Data were analyzed by applying the appropriate DNA fit algorithm using FCS3 Express software (De Novo software, USA).
Results
CD44s defines a distinct cell population in the SK-N-SH neuroblastoma cell line
Staining of the SK-N-SH neuroblastoma cell line for the standard isoform of CD44 (CD44s) revealed a distinct CD44-expressing subpopulation which constituted approximately 40% of the total population ( Fig. 1 ). These cells had a distinct Forward and Side Scatter distribution by flow cytometry, indicating higher size and granularity compared to cells lacking the antigen (Fig. 1a) . In order to purify these two populations we FACS-sorted SK-N-SH cells based on their CD44s expression ( Fig. 1b-d) . Following in vitro culture we observed that the CD44 positive and negative cell populations were morphologically different, with the CD44 positive cells adopting a more flattened morphology (Fig. 1e ) compared to the smaller size and neuronal projections of the moderately attached CD44 negative cells (Fig. 1f) . During in vitro propagation we noticed that the growth of CD44 positive cells occurred at a faster pace with an estimated doubling time of 2.5± 0.6 days, compared to CD44 negative cells that divided every 4.1±1.4 days (p<0.04) (Fig. 1g) . This was supported by cell proliferation analysis measuring the formazan levels of live cells, which indicated a 60% slower proliferation rate of the CD44 negative cells relative to the CD44 positive cells over a period of 48-72 h (p<0.05) (data not shown). Collectively, these findings indicated that CD44 antigen expression identified two morphologically distinct neuroblastoma cell populations with different growth properties. To further investigate CD44 variant expression in these two subpopulations, we performed RT-PCR as previously described [9] . mRNA for the standard CD44 isoform was abundantly expressed by the CD44 positive SK-N-SH cells which also expressed traces of CD44 variants 3, 5, 6 and 9 (Fig. 1h) . Semi-quantitative estimation of the different transcripts indicated that CD44 variants 5 and 6 were expressed at approximately 30-fold lower levels, and variants 3 and 9 at 100-fold lower levels compared to the standard isoform (data not shown). CD44 negative cells did not express any mRNA of the standard isoform and only exhibited a 340 bp band for CD44 variant 9 at lower levels compared to CD44 positive cells. This low abundance of the variant 9 transcript was not considered to significantly affect the phenotype of CD44 negative cells. No expression of variants 7 or 8 could be detected in any of the CD44-sorted cell populations (data not shown).
CD44 negative neuroblastoma cells possess a distinct adhesion molecule profile
To further characterize the cell surface profile of the CD44 positive and negative neuroblastoma cells we examined the expression of various adhesion molecules. The CD44 positive cells expressed two-fold higher levels of CD49d (α4 integrin), CD49e (α5 integrin) and CD29 (β1 integrin), and 4-fold higher levels of ICAM1 compared to the CD44 negative cells as determined by FACS Mean Fluorescence Intensity (MFI) (Fig. 2) . These findings may partly explain the higher adherence to tissue culture plastic and also the extended trypsin treatment required for this population to detach, compared to the CD44 negative cells (data not shown). In contrast, the CD44 negative cell population expressed higher levels of CD24 (MFI: 31.7) compared to the CD44 positive cells (MFI: 2.4), a molecule associated with high-risk neuroblastomas [18] . In addition, the CD44 negative cells express higher levels (MFI: 15.4) of the neural cell adhesion molecule NCAM which correlates with enhanced cell motility [19] and reduced adhesion to endothelial cells [20] . Therefore, the distinct cell adhesion profile of CD44 negative cells suggests an enhanced metastatic potential.
CD44 negative neuroblastoma cells develop subcutaneous tumors and micrometastases in NOD/SCID animals
To investigate whether the standard isoform of CD44 can be used to isolate neuroblastoma cells capable of tumor development in vivo, the FACS-sorted CD44 positive and CD44 negative SK-N-SH cells (Fig. 1) were subcutaneously injected in NOD/SCID animals. To prevent clearance of antibody-labeled neuroblastoma cells via NK antibodymediated cell cytotoxicity in NOD/SCID animals [21] , CD44 sorted cells were cultured in vitro prior to transplan- (Table 1) . Regardless of the initial cell number inoculum (10 4 , 5×10 4 or 10 5 ), only 1/11 mice that received CD44 positive SK-N-SH cells developed a subcutaneous tumor (p=0.01 chi-square test). This finding indicated that the neuroblastoma cells capable of tumor formation in vivo lacked expression of CD44. This result is in accordance with reports associating the unfavorable prognosis of neuroblastoma with lack of CD44 expression [22] .
In order to test whether the phenotype of the transplanted cells had changed following tumor development, we analyzed for the presence of CD44 in the subcutaneous tumors. In all tumors examined, only a small fraction of cells (7.9±5.6%) were positive for CD44, indicating that CD44 expression had not changed considerably following inoculation (Fig. 3a) . Subsequently, we tested the ability of CD44 negative and CD44 positive cells to invade other tissues by performing genomic PCR for the presence of human CART-1 gene. We tested the bone marrow, spleen and liver of all transplanted animals with or without subcutaneous tumors. We could detect human cells in the bone marrow, spleen and liver in 40%, 33% and 57% respectively of animals transplanted with CD44 negative cells (Fig. 3b) . In contrast, only 10% of animals (1/10) that had received CD44 positive neuroblastoma cells, developed micrometastases in the bone marrow and liver 2-3 months post-transplantation. These findings clearly indicated that neuroblastoma cells lacking CD44 were capable of organ infiltration.
CD44 defines molecularly distinct neuroblastoma cell populations
In order to molecularly characterize the CD44 negative and positive SK-N-SH neuroblastoma cells, we performed gene expression analysis using the Signal Transduction Pathway Finder Super Arrays (SA Biosciences). The CD44 negative cell population exhibited lower mRNA levels of the adhesion molecules VCAM1 (−28.56) and Fibronectin 1 (FN1 -14.08) compared to the CD44 positive cells, as well as ICAM1 (−51.13), further supporting the flow cytometry data depicted in Fig. 2 (Table 2) . Combined with the reduced integrin expression (Fig. 2) , these results indicated an overall diminished adhesion capacity of the CD44 negative cell population that may explain its metastatic propensity. Also the CD44 negative cells exhibited signs of reduced ability to undergo apoptosis, as they expressed higher levels of the NLR apoptosis inhibitory protein (NAIP +5.15) and lower levels of the apoptotic activators BCL-xL (−11.13), BAX (−2.65) and interferon regulatory Table 2 ). The elevated propensity of CD44 negative cells to progress through the cell cycle was verified by higher mRNA expression levels of CyclinA2 (+8.4), CDK2 (+5.7) and CDK4 (+1.95) by Quantitative Taqman PCR (Fig. 4a) . Cell cycle analysis of CD44 positive and CD44 negative cells under steady state revealed similar proportions of cells in the cell cycle phases (G1: 63±9% vs 56± 12%; S: 28±9% vs 36±11%; G2/M: 9±1% vs 8±3%) (Fig. 4b) . However, when we treated the cells with the drug 5-fluorouracil (5-FU), which induces a p53-mediated G1/S transition arrest, the CD44 positive neuroblastoma cells were retained in G1 (67%) and S (33%) phases, while the CD44 negative cells progressed through the cell cycle (G1: 36%; S: 40%; G2/M: 24%), clearly demonstrating the differential behavior of the two neuroblastoma cell populations to cytostatic drug treatment.
Discussion
Neuroblastoma is a childhood tumor that originates from the neural crest and presents with clinical heterogeneity, ranging from aggressive metastatic tumors to tumors that spontaneously regress. The diverse clinical outcome, the variable metastatic profile and most importantly the susceptibility for disease relapse may be explained by the existence of a small cell population with stem cell-like properties. In the present study we used the SK-N-SH cell line [23] to investigate the potential role of the standard isoform of CD44 as a marker to distinguish neuroblastoma cells with tumor-initiating properties. The SK-N-SH cell line constitutes a good model for studying tumor-initiating cells as it contains the malignant neuroblastoma intermediate-type (I-type) cells [24] and a side population (SP) of cells capable of effluxing the Hoechst 33342 dye, a property associated with the neuroblastoma stem cell phenotype [5] . Recently the CD133+ SK-N-SH cell fraction was shown to be resistant to common chemotherapeutic drugs, a further indication to the presence of tumorinitiating cells in this cell line [25] . Neuroblastoma is generally characterized by phenotypic variability, and neuroblastoma cell lines contain clones of neuronal (N-type cells), substrate-adherent (S-type cells) and intermediate (I-type cells) cell phenotype, that exhibit variable differentiation and tumor formation ability [26] . CD44s expression is high in S-type cells [16, 27] and more variable in N-and I-type phenotypic subclones [28] . Given the extended literature on the characterization of these subclones, our CD44-sorted cell populations probably contain a mixture of all three cell types. However, we illustrate that CD44 can be used to further purify these phenotypic variants and to distinguish the in vivo neuroblastoma-initiating cells.
Gross and colleagues (2000) elegantly showed that in neuroblastoma enforced expression or amplification of Nmyc abrogates the function of CD44 and results in enhanced tumor formation, indicating the association between the two molecules [22] . We have verified that neuroblastoma cells negative for CD44 form tumors in vivo and have further shown that SK-N-SH cells lacking CD44 express higher levels of CD24. This provides further support to the malignant phenotype of the CD44 negative cell population, as CD24 has been associated with the tumor-initiating property of tumor spheres cultured from neuroblastoma bone marrow metastases [18] .
CD44s is a favorable prognostic factor in neuroblastoma [14, 15] and the epigenetic inactivation of CD44 expression through methylation has been reported as a potential culprit in the process of neuroblastoma development [29, 30] . In the xenograft model, inhibitors of DNA methylation as well as induction of CD44 expression suppress neuroblastoma growth [31] . Clinical studies have associated CD44 expression with low-stage differentiated neuroblastoma while high-risk aggressive tumors lack expression of this antigen [28] . In this study, we have demonstrated that CD44s can be used as a marker to isolate neuroblastoma cells capable of subcutaneous xenograft formation and organ infiltration in NOD/SCID animals; in addition we provide evidence that these tumors remained negative for CD44.
We verified that CD44 negative SK-N-SH cells did not express significant amounts of CD44 variant isoforms and showed that lack of CD44 expression was accompanied by lower levels of various adhesion molecules, including CD49d (α4 integrin), CD49e (α5 integrin) and CD29 (β1 integrin), as well as ICAM1 and NCAM. Such reduced adherence capacity may enhance the cells' migratory ability and their propensity to form metastases [19, 20] . Our in vivo data following subcutaneous neuroblastoma cell inoculation in NOD/SCID animals corroborate with such hypothesis. Although CD44 mediates the trans-endothelial migration of hematopoietic stem/progenitor cells [32] , we found that the CD44 negative neuroblastoma cells were the ones that infiltrated the BM, spleen and liver of transplanted animals clearly showing that the metastatic ability of neuroblastoma cells is not dependent on CD44. CD44 negative SK-N-SH cells were readily detectable in bone marrow, spleen and liver up to 4 months following tumor cell inoculation. In contrast, CD44 positive neuroblastoma cells only formed subcutaneous tumors in 1/11 animals and could be detected in the BM and liver of 1/10 recipient animals. Our data contradicts a recent report showing that CD44 positive neuroblastoma cell lines (SK-N-SH, IMR32, Kelly) form metastases more efficiently than CD44 negative lines in a xenotransplantation model [33] without, however, accounting for the CD44 expression purity of the transplanted cells. We also molecularly characterized the tumorigenic CD44 negative neuroblastoma population by performing gene expression analysis to identify distinct pathways that differentiate CD44 negative from CD44-expressing SK-N-SH neuroblastoma cells. We found that cells lacking CD44 expressed lower levels of cell cycle inhibitors (p21 Cip1 , p16
INK4a
, p15 INK4b ), and lower levels of the apoptotic activators NAIP, BCL-xL, BAX and IRF1, indicating uncontrolled cell cycle progression and resistance to apoptosis. In addition, 5-fluorouracil treatment prompted the CD44 negative cells to proceed to G2 contrary to the G1 cell cycle arrest seen in CD44 positive cells. A further property of cancer-initiating cells is the ability to evade host immunity during tumor establishment. CD44 negative neuroblastoma cells demonstrated such a profile by expressing reduced levels of the chemo-attractant CCL2 and the TNF receptor FAS [34, 35] .
Undoubtedly, demonstration of the tumor-initiating ability of the CD44 negative cells needs to be extended to patient samples and possibly in model systems allowing tumor formation by a single cell. Nonetheless, our findings are in accordance with neuroblastoma patient reports validating the prognostic value of CD44s expression. Identification of the phenotype of cancer-initiating cells has significant therapeutic implications. We reveal that the cells capable of neuroblastoma development in vivo contain a unique phenotypic and molecular profile which allows resistance to apoptosis, evade host immunity and undergo uncontrollable cell cycle progression. All these features not only unequivocally support the ability of the CD44 negative cell population to establish and propagate neuroblastoma in vivo, but also determine pathways for potential therapeutic intervention. 
